Carol G Hooper, MD | |
2501 Oakington St, Aberdeen Proving Ground, MD 21005-5131 | |
(140) 278-1727 | |
Not Available |
Full Name | Carol G Hooper |
---|---|
Gender | Female |
Speciality | Family Medicine |
Location | 2501 Oakington St, Aberdeen Proving Ground, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083685713 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | D28628 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Carol G Hooper, MD 2501 Oakington St, Aberdeen Proving Ground, MD 21005-5131 Ph: (140) 278-1727 | Carol G Hooper, MD 2501 Oakington St, Aberdeen Proving Ground, MD 21005-5131 Ph: (140) 278-1727 |
News Archive
Washington's Reproductive Parity Act would be the first state law to require insurance plans to cover abortion.
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.
Jeffery Dusek, PhD, Director of Research at University Hospitals (UH) Connor Integrative Health Network and Associate Professor in the Department of Family Medicine and Community Health at Case Western Reserve University, and colleagues were recently awarded a 3-year, $2+ million grant from the National Center of Complementary and Integrative Health, part of the National Institutes of Health.
A multinational team effort of Regensburg's Institute of Human Genetics, Washington University in St. Louis, other partners and Genomatix elucidated a transcriptional network in photoreceptors and thereby identified a novel retinal disease gene
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.
› Verified 2 days ago
Joseph V. Perugino, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2501 Oakington St, Aberdeen Proving Ground, MD 21005 Phone: 410-278-1813 | |
Melinda Marilyn Reed-linton, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2501 Oakington St, Aberdeen Proving Ground, MD 21005 Phone: 410-278-1813 |